Investment analysts at StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “buy” rating on the stock.
MEI Pharma Trading Up 1.3 %
Shares of MEI Pharma stock opened at $2.33 on Friday. The firm has a market capitalization of $15.53 million, a PE ratio of -0.41 and a beta of 0.76. The firm’s 50 day moving average is $2.67 and its 200 day moving average is $2.77. MEI Pharma has a 1 year low of $2.30 and a 1 year high of $4.15.
MEI Pharma (NASDAQ:MEIP – Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.48) earnings per share (EPS) for the quarter. As a group, research analysts anticipate that MEI Pharma will post -5.1 earnings per share for the current year.
Institutional Investors Weigh In On MEI Pharma
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
See Also
- Five stocks we like better than MEI Pharma
- Investing in the High PE Growth Stocks
- How to Build the Ultimate Everything ETF Portfolio
- 3 Fintech Stocks With Good 2021 Prospects
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is Forex and How Does it Work?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.